Lorlatinib for ROS1-positive lung cancer with brain spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests an oral drug called lorlatinib in people with ROS1-positive lung cancer that has spread to the brain. The drug targets the ROS1 mutation and aims to shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- Your lung cancer must have a change called ROS1 (a special gene alteration)
- The cancer must have spread to your brain (seen on an MRI or CT scan)
- You must not have had many previous treatments - either none at all or just one round of chemotherapy with platinum drugs
- You need to be in fairly good health, able to do most daily activities
- You must have at least one measurable tumor in the brain that is 5 mm or larger
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This study looks at how often lorlatinib, a targeted therapy for ALK-positive lung cancer, causes side effects in the brain or nervous system. Researchers hope to find risk factors so doctors can better monitor and manage these effects.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.